Day One Biopharmaceuticals Receives HSR Clearance for Servier Tender Offer

summarizeSummary

Day One Biopharmaceuticals announced that a key regulatory condition for its acquisition by Servier has been satisfied, moving the tender offer closer to completion.

check_boxKey Events

• HSR Act Clearance Granted

  The Federal Trade Commission (FTC) granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, effective April 7, 2026.

• Tender Offer Condition Satisfied

  This regulatory approval satisfies a key condition for Servier's tender offer to acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share, as initially announced on March 26, 2026.

auto_awesomeAnalysis

This amendment confirms that the Federal Trade Commission (FTC) has granted early termination of the waiting period under the HSR Act, a critical regulatory approval for Servier's tender offer to acquire Day One Biopharmaceuticals. The satisfaction of this condition removes a significant hurdle, increasing the certainty and accelerating the timeline for the acquisition to close. This is a positive development for shareholders awaiting the completion of the $21.50 per share all-cash offer.